<DOC>
	<DOCNO>NCT00262743</DOCNO>
	<brief_summary>RATIONALE : Green tea extract contain ingredient may slow growth certain cancer . PURPOSE : This phase I/II trial study side effect best dose green tea extract see well work treat patient stage 0 , stage I , stage II chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Green Tea Extract Treating Patients With Stage 0 , Stage I , Stage II Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Phase I - Determine maximally tolerate dose green tea extract ( Polyphenon E ) patient previously untreated stage 0-II chronic lymphocytic leukemia . - Describe dose-limiting toxicity green tea extract ( Polyphenon E ) . Phase II - Evaluate response rate response duration patient previously untreated , asymptomatic Rai stage 0-II chronic lymphocytic leukemia treat green tea extract ( Polyphenon E ) 6 month MTD . - Further characterize toxicity . OUTLINE : This phase I , dose-escalation study green tea extract ( Polyphenon E ) follow phase II study . - Phase I : Patients receive oral green tea extract ( Polyphenon E ) twice daily 4 week . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos green tea extract ( Polyphenon E ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive green tea extract ( Polyphenon E ) phase I portion study MTD . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 73 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis chronic lymphocytic leukemia ( CLL ) Stage 0 , I , II disease Previously untreated disease Splenomegaly , hepatomegaly , lymphadenopathy require diagnosis CLL Absolute lymphocyte count &gt; 10,000/mm^3 Lymphocytosis must consist small moderate size lymphocyte , ≤ 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Phenotypically characterize BCLL define follow criterion : A population leukemic cell coexpresses Bcell antigen CD23 well CD5 absence Tcell marker ( CD3 , CD2 , etc . ) Dim surface immunoglobulin expression Exclusively κ λ light chain Mantle cell lymphoma must exclude demonstrate absence ( 11:14 ) FISH test Patients require chemotherapy treatment CLL , base follow criterion , exclude : CLLrelated symptom require treatment , include follow : Unintentional weight loss ≥ 10 % body weight within previous 6 month Extreme fatigue Fevers &gt; 100.5°F 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure due CLL involvement bone marrow manifest development worsen anemia ( hemoglobin &lt; 11 g/dl ) and/or thrombocytopenia ( platelet count &lt; 100,000/mm^3 ) Thrombocytopenia due immune phenomenon ( ITP ) permit long platelet count ≥ 100,000/mm^3and patient active pharmacologic therapy Massive ( i.e . &gt; 6 cm leave costal margin ) progressive splenomegaly Massive nod cluster ( i.e. , &gt; 10 cm long diameter ) progressive adenopathy Progressive lymphocytosis increase &gt; 50 % 2 month period , anticipated lymphocyte double time &lt; 6 month PATIENT CHARACTERISTICS : Platelet count ≥ 100,000/µL ANC ≥ 1500/µL Hemoglobin ≥ 11 g/dL Total direct bilirubin ≤ 1.5 x upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) ≤ 2 x ULN Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 40 mL/min May history autoimmune hemolytic anemia ( AIHA ) positive Coombs test provide active hemolysis require transfusion steroid treatment ≤ 10 week prior registration ECOG performance status 0 , 1 , 2 Life expectancy ≥ 6 month No uncontrolled infection No myocardial infarction within past 6 week No New York Heart Association class III IV congestive heart failure Not pregnant nursing Negative pregnancy test Must employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) prior study entry duration study participation No severe medical psychiatric illness No active hemolysis require transfusion pharmacologic therapy PRIOR CONCURRENT THERAPY : At least 8 week since prior concurrent counter green tea green tea extract No prior daily use counter green tea product medicinal purpose &gt; 4 week ( phase II ) No concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation ) No concurrent combination antiretroviral therapy HIV positive patient No concurrent oral steroid preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
</DOC>